MarketVector rolled out stablecoin and real-world asset tokenization indexes, alongside new ETFs from Amplify that track the ...
Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, ...
Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback